NCT04901195已完成3 期
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 658
- 试验地点
- 296
- 主要终点
- Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
研究概览
简要总结
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Study participant has completed the Maintenance Treatment Period through Week 48 in HS0003 (NCT04242446) or HS0004 (NCT04242498), was eligible to receive bimekizumab at the time of completing the feeder study, and did not meet any withdrawal criteria of the feeder study
- •Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator
- •A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- •Not a woman of childbearing potential (WOCBP) OR
- •A WOCBP who agrees to follow the contraceptive guidance during the open-label extension period and for at least 20 weeks after the final dose of investigational medicinal product (IMP)
排除标准
- •Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)
- •Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments Note: For any study participant with an ongoing serious adverse event (SAE) from HS0003 (NCT04242446) or HS0004 (NCT04242498), or any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry or a history of serious infections in HS0003 or HS0004, the Medical Monitor must be consulted prior to the study participant's entry into HS0005, although the decision on whether to enroll the participant remains with the Investigator.
- •Study participant has a positive or indeterminate interferon-gamma release assay (IGRA) in a feeder study, unless appropriately evaluated and treated
- •Study participant has ongoing or planned use of prohibited hidradenitis suppurativa (HS) or non-HS treatment
- •Study participant plans to participate in another study of a medicinal product or device under investigation during this study
研究组 & 干预措施
Bimekizumab dosing regimen 1
Experimental
Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the open-label extension period.
干预措施: Bimekizumab (Drug)
Bimekizumab dosing regimen 2
Experimental
Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the open-label extension period.
干预措施: Bimekizumab (Drug)
结局指标
主要结局
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
时间窗: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
次要结局
- Percentage of participants with treatment-emergent serious adverse events (SAEs) during the study(From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196))
- Percentage of participants with Flare(Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180)
- Percentage of participants with treatment-emergent adverse events (TEAEs) leading to withdrawal from the study(From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196))
- Percentage of participants achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)(Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180)
- Percentage of participants achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)(Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180)
- Hidradenitis Suppurativa Symptom Questionnaire (HSSQ) Response for Worst Pain(Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180)
- Absolute change from Baseline in Dermatology Life Quality Index (DLQI) Total Score(Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180)
研究者
研究点 (296)
Loading locations...
相似试验
已完成
3 期
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisPsoriatic ArthritisNCT04009499UCB Biopharma SRL1,131
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT03928743UCB Biopharma SRL332
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial SpondyloarthritisNonradiographic Axial SpondyloarthritisNCT03928704UCB Biopharma SRL274
已完成
3 期
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisPsoriatic ArthritisNCT03895203UCB Biopharma SRL852
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisChronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisNCT03598790UCB Biopharma SRL1,353